The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Abstract
During the past decades, better understanding of relapsing-remitting multiple sclerosis disease mechanisms have led to the development of several disease-modifying therapies, reducing relapse rates and severity, through immune system modulation or suppression. In contrast, current therapeutic options for progressive multiple sclerosis remain comparatively disappointing and challenging. One possible explanation is a lack of understanding of pathogenic mechanisms driving progressive multiple sclerosis. Furthermore, diagnosis is usually retrospective, based on history of gradual neurological worsening with or without occasional relapses, minor remissions or plateaus. In addition, imaging methods as well as biomarkers are not well established. Magnetic resonance imaging studies in progressive multiple sclerosis show decreased blood-brain barrier permeability, probably reflecting compartmentalization of inflammation behind a relatively intact blood-brain barrier. Interestingly, a spectrum of inflammatory cell types infiltrates the leptomeninges during subpial cortical demyelination. Indeed, recent magnetic resonance imaging studies show leptomeningeal contrast enhancement in subjects with progressive multiple sclerosis, possibly representing an in vivo marker of inflammation associated to subpial demyelination. Treatments for progressive disease depend on underlying mechanisms causing central nervous system damage. Immunity sheltered behind an intact blood-brain barrier, energy failure, and membrane channel dysfunction may be key processes in progressive disease. Interfering with these mechanisms may provide neuroprotection and prevent disability progression, while potentially restoring activity and conduction along damaged axons by repairing myelin. Although most previous clinical trials in progressive multiple sclerosis have yielded disappointing results, important lessons have been learnt, improving the design of novel ones. This review discusses mechanisms involved in progressive multiple sclerosis, correlations between histopathology and magnetic resonance imaging studies, along with possible new therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · cited 2×
“Most phagocytic cells present ramified microglia morphology and appear in close apposition to neurites and neuronal cell bodies (Peterson et al., 2001).”
BackgroundSerafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
Barnett, M. H., & Prineas, J. W. (2004) · Annals of Neurology · doi:10.1002/ana.20016 · Cited by 1,185
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Multiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
Lymphoid neogenesis in chronic inflammatory diseases
Aloisi, F., & Pujol-Borrell, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1786 · Cited by 908
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
Schmierer, K., Scaravilli, F., Altmann, D. R., Barker, G. J., & Miller, D. H. (2004) · Annals of Neurology · doi:10.1002/ana.20202 · Cited by 776
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Cellular responses to viral infection in humans: lessons from Epstein–Barr virus
Hislop, A. D., Taylor, G. S., Sauce, D., & Rickinson, A. B. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141553 · Cited by 766
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Oxidative damage in multiple sclerosis lesions
Haider, L., Fischer, M. T., Frischer, J. M., Bauer, J., Hoftberger, R., Botond, G., Esterbauer, H., Binder, C. J., Witztum, J. L., & Lassmann, H. (2011) · Brain · doi:10.1093/brain/awr128 · Cited by 753
A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
Magliozzi, R., Howell, O. W., Reeves, C., Roncaroli, F., Nicholas, R., Serafini, B., Aloisi, F., & Reynolds, R. (2010) · Annals of Neurology · doi:10.1002/ana.22230 · Cited by 747
Glutamate excitotoxicity in a model of multiple sclerosis
Pitt, D., Werner, P., & Raine, C. S. (2000) · Nature Medicine · doi:10.1038/71555 · Cited by 744
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T., & Kerschensteiner, M. (2011) · Nature Medicine · doi:10.1038/nm.2324 · Cited by 713 · cited 1×
“In addition, direct damage to neurons occurs through reactive oxygen and nitrogen species (ROS/NRS) produced by microglia, inducing mitochondrial dysfunction (see below) (Nikic et al., 2011).”
BackgroundScalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
Gray matter atrophy in multiple sclerosis: A longitudinal study
Fisher, E., Lee, J., Nakamura, K., & Rudick, R. A. (2008) · Annals of Neurology · doi:10.1002/ana.21436 · Cited by 670
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621
Diffusion tensor magnetic resonance imaging in multiple sclerosis
Filippi, M., Cercignani, M., Inglese, M., Horsfield, M. A., & Comi, G. (2001) · Neurology · doi:10.1212/wnl.56.3.304 · Cited by 546
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
Bar‐Or, A., Fawaz, L., Fan, B., Darlington, P. J., Rieger, A., Ghorayeb, C., Calabresi, P. A., Waubant, E., Hauser, S. L., Zhang, J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21939 · Cited by 521
Iron and neurodegeneration in the multiple sclerosis brain
Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S., Brück, W., & Lassmann, H. (2013) · Annals of Neurology · doi:10.1002/ana.23974 · Cited by 519
Grey matter pathology in multiple sclerosis
Geurts, J. J., & Barkhof, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70191-1 · Cited by 507
Gray matter atrophy is related to long‐term disability in multiple sclerosis
Fisniku, L. K., Chard, D. T., Jackson, J. S., Anderson, V. M., Altmann, D. R., Miszkiel, K. A., Thompson, A. J., & Miller, D. H. (2008) · Annals of Neurology · doi:10.1002/ana.21423 · Cited by 500
Mi, S., Hu, B., Hahm, K., Luo, Y., Kam Hui, E. S., Yuan, Q., Wong, W. M., Wang, L., Su, H., Chu, T.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1664 · Cited by 492
Imaging axonal damage of normal-appearing white matter in multiple sclerosis
Fu, L. (1998) · Brain · doi:10.1093/brain/121.1.103 · Cited by 481
Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration
Bø, L., Vedeler, C. A., Nyland, H., Trapp, B. D., & Mørk, S. J. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms917oa · Cited by 478
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation
Mayo, L., Trauger, S. A., Blain, M., Nadeau, M., Patel, B., Alvarez, J. I., Mascanfroni, I. D., Yeste, A., Kivisäkk, P., Kallas, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3681 · Cited by 472
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Mitochondrial changes within axons in multiple sclerosis
Mahad, D. J., Ziabreva, I., Campbell, G., Lax, N., White, K., Hanson, P. S., Lassmann, H., & Turnbull, D. M. (2009) · Brain · doi:10.1093/brain/awp046 · Cited by 454
Lublin, F., Miller, D. H., Freedman, M. S., Cree, B. A. C., Wolinsky, J. S., Weiner, H., Lubetzki, C., Hartung, H.-P., Montalban, X., Uitdehaag, B. M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01314-8 · Cited by 448
Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Pathogenesis of axonal and neuronal damage in multiple sclerosis
Dutta, R., & Trapp, B. D. (2007) · Neurology · doi:10.1212/01.wnl.0000275229.13012.32 · Cited by 412
Friese, M. A., Craner, M. J., Etzensperger, R., Vergo, S., Wemmie, J. A., Welsh, M. J., Vincent, A., & Fugger, L. (2007) · Nature Medicine · doi:10.1038/nm1668 · Cited by 408
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.
Geurts, J. J. G., Bø, L., Pouwels, P. J. W., Castelijns, J. A., Polman, C. H., & Barkhof, F. (2005) · PubMed · Cited by 407
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Cohen, J. A., Cutter, G. R., Fischer, J. S., Goodman, A. D., Heidenreich, F. R., Kooijmans, M. F., Sandrock, A. W., Rudick, R. A., Simon, J. H., Simonian, N. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.5.679 · Cited by 402
Axonal conduction and injury in multiple sclerosis: the role of sodium channels
Waxman, S. G. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn2023 · Cited by 397
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Choi, S. R., Howell, O. W., Carassiti, D., Magliozzi, R., Gveric, D., Muraro, P. A., Nicholas, R., Roncaroli, F., & Reynolds, R. (2012) · Brain · doi:10.1093/brain/aws189 · Cited by 386
Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis
Campbell, G. R., Ziabreva, I., Reeve, A. K., Krishnan, K. J., Reynolds, R., Howell, O., Lassmann, H., Turnbull, D. M., & Mahad, D. J. (2011) · Annals of Neurology · doi:10.1002/ana.22109 · Cited by 386
Kotter, M. R., Setzu, A., Sim, F. J., Van Rooijen, N., & Franklin, R. J. M. (2001) · Glia · doi:10.1002/glia.1085 · Cited by 385
Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes
Kassmann, C. M., Lappe-Siefke, C., Baes, M., Brügger, B., Mildner, A., Werner, H. B., Natt, O., Michaelis, T., Prinz, M., Frahm, J., et al. (2007) · Nature Genetics · doi:10.1038/ng2070 · Cited by 357
Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes
Matute, C., Sánchez-Gómez, M. V., Martínez-Millán, L., & Miledi, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8830 · Cited by 352 · cited 1×
“Consequently, pathologically elevated levels of extracellular glutamate are found, which are directly toxic to oligodendrocytes, axons and neurons (Matute et al., 1997).”
BackgroundWilkins, A., Majed, H., Layfield, R., Compston, A., & Chandran, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04967.2003 · Cited by 337
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Electrically active axons degenerate when exposed to nitric oxide
Smith, K. J., Kapoor, R., Hall, S. M., & Davies, M. (2001) · Annals of Neurology · doi:10.1002/ana.96 · Cited by 320
Demyelination versus remyelination in progressive multiple sclerosis
Bramow, S., Frischer, J. M., Lassmann, H., Koch-Henriksen, N., Lucchinetti, C. F., Sørensen, P. S., & Laursen, H. (2010) · Brain · doi:10.1093/brain/awq250 · Cited by 319
General mechanisms of axonal damage and its prevention
Stys, P. K. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.031 · Cited by 314
Disease-specific molecular events in cortical multiple sclerosis lesions
Fischer, M. T., Wimmer, I., Höftberger, R., Gerlach, S., Haider, L., Zrzavy, T., Hametner, S., Mahad, D., Binder, C. J., Krumbholz, M., et al. (2013) · Brain · doi:10.1093/brain/awt110 · Cited by 311
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI
Geurts, J. J. G., Roosendaal, S. D., Calabrese, M., Ciccarelli, O., Agosta, F., Chard, D. T., Gass, A., Huerga, E., Moraal, B., Pareto, D., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0cc4 · Cited by 310
Secondary progressive multiple sclerosis: current knowledge and future challenges
Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., & Filippi, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70410-0 · Cited by 303
Harris, J. O., Frank, J. A., Patronas, N., McFarlin, D. E., & McFarland, H. F. (1991) · Annals of Neurology · doi:10.1002/ana.410290515 · Cited by 303
Multiple sclerosis normal‐appearing white matter: Pathology–imaging correlations
Moll, N. M., Rietsch, A. M., Thomas, S., Ransohoff, A. J., Lee, J., Fox, R., Chang, A., Ransohoff, R. M., & Fisher, E. (2011) · Annals of Neurology · doi:10.1002/ana.22521 · Cited by 297
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis
Absinta, M., Vuolo, L., Rao, A., Nair, G., Sati, P., Cortese, I. C. M., Ohayon, J., Fenton, K., Reyes-Mantilla, M. I., Maric, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001587 · Cited by 296 · cited 2×
“Reproduced with permission from Absinta et al. (2015). by guest on O ctober 29, 2016 http://brain.oxfordjournals.org/ D ow nloaded from as absence of adequate animal models, make identification of potential target pathways and new treatment agents difficult.”
BackgroundA comparison of the pathology of primary and secondary progressive multiple sclerosis
Revesz, T., Kidd, D., Thompson, A. J., Barnard, R. O., & McDonald, W. I. (1994) · Brain · doi:10.1093/brain/117.4.759 · Cited by 293
Multiple sclerosis: gadolinium enhancement in MR imaging.
Grossman, R. I., Gonzalez-Scarano, F., Atlas, S. W., Galetta, S., & Silberberg, D. H. (1986) · Radiology · doi:10.1148/radiology.161.3.3786722 · Cited by 289
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.
Thompson, A. J., Kermode, A. G., MacManus, D. G., Kendall, B. E., Kingsley, D. P., Moseley, I. F., & McDonald, W. I. (1990) · BMJ · doi:10.1136/bmj.300.6725.631 · Cited by 288
De Groot, C. J. A. (2001) · Brain · doi:10.1093/brain/124.8.1635 · Cited by 285
Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain
Willis, S. N., Stadelmann, C., Rodig, S. J., Caron, T., Gattenloehner, S., Mallozzi, S. S., Roughan, J. E., Almendinger, S. E., Blewett, M. M., Brück, W., et al. (2009) · Brain · doi:10.1093/brain/awp200 · Cited by 284
Demyelination, Inflammation, and Neurodegeneration in Multiple Sclerosis Deep Gray Matter
Vercellino, M., Masera, S., Lorenzatti, M., Condello, C., Merola, A., Mattioda, A., Tribolo, A., Capello, E., Mancardi, G. L., Mutani, R., et al. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a19a5a · Cited by 277
Mitochondrial Dysfunction and Glutamate Excitotoxicity Studied in Primary Neuronal Cultures
Nicholls, D. (2004) · Current Molecular Medicine · doi:10.2174/1566524043479239 · Cited by 272
The Role of Astrocytes in Multiple Sclerosis Progression
Correale, J., & Farez, M. F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00180 · Cited by 261
Self-citationEpstein–Barr Virus Infection and Multiple Sclerosis: A Review
Ascherio, A., & Munger, K. L. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9201-3 · Cited by 259
Interferon β-1a in primary progressive MS: An exploratory, randomized, controlled trial
Leary, S. M., Miller, D. H., Stevenson, V. L., Brex, P. A., Chard, D. T., & Thompson, A. J. (2003) · Neurology · doi:10.1212/wnl.60.1.44 · Cited by 251
Relapsing and progressive forms of multiple sclerosis: insights from pathology
Dutta, R., & Trapp, B. D. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000094 · Cited by 242
Camp, S. J., Stevenson, V. L., Thompson, A. J., Miller, D. H., Borras, C., Auriacombe, S., Brochet, B., Falautano, M., Filippi, M., Herisse-Dulo, L., et al. (1999) · Brain · doi:10.1093/brain/122.7.1341 · Cited by 234
Spinal-cord MRI in multiple sclerosis
Lycklama, G., Thompson, A., Filippi, M., Miller, D., Polman, C., Fazekas, F., & Barkhof, F. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00504-0 · Cited by 231
Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis
Lovato, L., Willis, S. N., Rodig, S. J., Caron, T., Almendinger, S. E., Howell, O. W., Reynolds, R., O’Connor, K. C., & Hafler, D. A. (2011) · Brain · doi:10.1093/brain/awq350 · Cited by 223
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
Ontaneda, D., Fox, R. J., & Chataway, J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70264-9 · Cited by 220
Paolillo, A., Coles, A. J., Molyneux, P. D., Gawne–Cain, M., MacManus, D., Barker, G. J., Compston, D. A. S., & Miller, D. H. (1999) · Neurology · doi:10.1212/wnl.53.4.751 · Cited by 220
Vulnerability of Human Neurons to T Cell-Mediated Cytotoxicity
Giuliani, F., Goodyer, C. G., Antel, J. P., & Yong, V. W. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.368 · Cited by 215
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel, J., Antel, S., Caramanos, Z., Arnold, D. L., & Kuhlmann, T. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0953-0 · Cited by 215
INSENSITIVITY OF RESPIRATORY CENTRE TO CARBON DIOXIDE IN THE ENGA PEOPLE OF NEW GUINEA
Beral, V., & Read, D. J. C. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90606-4 · Cited by 211
Imaging Cortical Lesions in Multiple Sclerosis With Ultra–High-Field Magnetic Resonance Imaging
Pitt, D., Boster, A., Pei, W., Wohleb, E., Jasne, A., Zachariah, C. R., Rammohan, K., Knopp, M. V., & Schmalbrock, P. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.148 · Cited by 210
Schattling, B., Steinbach, K., Thies, E., Kruse, M., Menigoz, A., Ufer, F., Flockerzi, V., Brück, W., Pongs, O., Vennekens, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.3015 · Cited by 206
Meningeal and cortical grey matter pathology in multiple sclerosis
Gh Popescu, B. F., & Lucchinetti, C. F. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-11 · Cited by 199
Spinal cord gray matter atrophy correlates with multiple sclerosis disability
Schlaeger, R., Papinutto, N., Panara, V., Bevan, C., Lobach, I. V., Bucci, M., Caverzasi, E., Gelfand, J. M., Green, A. J., Jordan, K. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24241 · Cited by 196
A new concept in neurodegeneration: TNFα is a silencer of survival signals
Venters, H. D., Dantzer, R., & Kelley, K. W. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01533-7 · Cited by 194
Axonal protection using flecainide in experimental autoimmune encephalomyelitis
Bechtold, D. A., Kapoor, R., & Smith, K. J. (2004) · Annals of Neurology · doi:10.1002/ana.20045 · Cited by 192
The natural history of multiple sclerosis: a geographically based study
Kremenchutzky, M., Cottrell, D., Rice, G., Hader, W., Baskerville, J., Koopman, W., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.10.1941 · Cited by 186
Sedel, F., Bernard, D., Mock, D. M., & Tourbah, A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.028 · Cited by 184
Bergendal, G., Fredrikson, S., & Almkvist, O. (2007) · European Neurology · doi:10.1159/000099158 · Cited by 184
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis
Katz Sand, I., Krieger, S., Farrell, C., & Miller, A. E. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514521517 · Cited by 182
Shouts, whispers and the kiss of death: directional secretion in T cells
Huse, M., Quann, E. J., & Davis, M. M. (2008) · Nature Immunology · doi:10.1038/ni.f.215 · Cited by 182
Mizuno, T., Zhang, G., Takeuchi, H., Kawanokuchi, J., Wang, J., Sonobe, Y., Jin, S., Takada, N., Komatsu, Y., & Suzumura, A. (2008) · The FASEB Journal · doi:10.1096/fj.07-099499 · Cited by 181
Goodin, D. S., Arnason, B. G. W., Coyle, P. K., Frohman, E. M., & Paty, D. W. (2003) · Neurology · doi:10.1212/01.wnl.0000095425.84407.39 · Cited by 178
Pagani, E., Rocca, M. A., Gallo, A., Rovaris, M., Martinelli, V., Comi, G., & Filippi, M. (2005) · PubMed · Cited by 178
Primary and transitional progressive MS: A clinical and MRI cross-sectional study
Stevenson, V. L., Miller, D. H., Rovaris, M., Barkhof, F., Brochet, B., Dousset, V., Dousset, V., Filippi, M., Montalban, X., Polman, C. H., et al. (1999) · Neurology · doi:10.1212/wnl.52.4.839 · Cited by 177
Thompson, A. J., Toosy, A. T., & Ciccarelli, O. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70249-0 · Cited by 175
Multiple sclerosis: Lessons from molecular neuropathology
Lassmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.12.003 · Cited by 172
Medana, I. M., Gallimore, A., Oxenius, A., Martinic, M. M. A., Wekerle, H., & Neumann, H. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3623::aid-immu3623>3.0.co;2-f · Cited by 171
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Brück, W., Pförtner, R., Pham, T., Zhang, J., Hayardeny, L., Piryatinsky, V., Hanisch, U.-K., Regen, T., van Rossum, D., Brakelmann, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1009-1 · Cited by 168
Vergo, S., Craner, M. J., Etzensperger, R., Attfield, K., Friese, M. A., Newcombe, J., Esiri, M., & Fugger, L. (2011) · Brain · doi:10.1093/brain/awq337 · Cited by 168
Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome
Kantarci, O. H., Lebrun, C., Siva, A., Keegan, M. B., Azevedo, C. J., Inglese, M., Tintoré, M., Newton, B. D., Durand‐Dubief, F., Amato, M. P., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24564 · Cited by 167
Absinta, M., Sati, P., Gaitán, M. I., Maggi, P., Cortese, I. C. M., Filippi, M., & Reich, D. S. (2013) · Annals of Neurology · doi:10.1002/ana.23959 · Cited by 166
Self-citationA gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging
Mainero, C., Louapre, C., Govindarajan, S. T., Giannì, C., Nielsen, A. S., Cohen-Adad, J., Sloane, J., & Kinkel, R. P. (2015) · Brain · doi:10.1093/brain/awv011 · Cited by 165
Marrie, R. A., Reider, N., Cohen, J., Stuve, O., Trojano, M., Cutter, G., Reingold, S., & Sorensen, P. S. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514564485 · Cited by 163
Agosta, F., Rovaris, M., Pagani, E., Sormani, M. P., Comi, G., & Filippi, M. (2006) · Brain · doi:10.1093/brain/awl208 · Cited by 163
Dysferlin Is a New Marker for Leaky Brain Blood Vessels in Multiple Sclerosis
Hochmeister, S., Grundtner, R., Bauer, J., Engelhardt, B., Lyck, R., Gordon, G., Korosec, T., Kutzelnigg, A., Berger, J. J., Bradl, M., et al. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000235119.52311.16 · Cited by 160
The central role of mitochondria in axonal degeneration in multiple sclerosis
Campbell, G. R., Worrall, J. T., & Mahad, D. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514544537 · Cited by 152
The role of microglial activation in disease progression
Correale, J. D. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514533230 · Cited by 151
Self-citationMagliozzi, R., Serafini, B., Rosicarelli, B., Chiappetta, G., Veroni, C., Reynolds, R., & Aloisi, F. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827bfc62 · Cited by 150
Rossi, S., Motta, C., Studer, V., Barbieri, F. R., Buttari, F., Bergami, A., Sancesario, G. M., Bernardini, S., Angelis, G. D., Martino, G., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513498128 · Cited by 149
Neurological deficits caused by tissue hypoxia in neuroinflammatory disease
Davies, A. L., Desai, R. A., Bloomfield, P. S., McIntosh, P. R., Chapple, K. J., Linington, C., Fairless, R., Diem, R., Kasti, M., Murphy, M. P., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24006 · Cited by 147
Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis
Kuenz, B., Lutterotti, A., Ehling, R., Gneiss, C., Hämmerle, M., Rainer, C., Deisenhammer, F., Schocke, M. F. H., Berger, T., & Reindl, M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002559 · Cited by 138
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033
Tran, J. Q., Rana, J., Barkhof, F., Melamed, I. R., Gevorkyan, H., Wattjes, M. P., de Jong, R., Brosofsky, K., Ray, S. S., Xu, L., et al. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000018 · Cited by 135
Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS
Nielsen, A. S., Kinkel, R. P., Madigan, N. K., Tinelli, E., Benner, T., & Mainero, C. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a08ce8 · Cited by 135
Axonal protection achieved in a model of multiple sclerosis using lamotrigine
Bechtold, D. A., Miller, S. J., Dawson, A. C., Sun, Y., Kapoor, R., Berry, D. J., & Smith, K. J. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0204-1 · Cited by 130
Andersen, O. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.010090 · Cited by 122
1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS
Suhy, J., Rooney, W. D., Goodkin, D. E., Capizzano, A. A., Soher, B. J., Maudsley, A. A., Waubant, E. L., Andersson, P.-B., & Weiner, M. W. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600303 · Cited by 117
Montalbán, X., Sastre‐Garriga, J., Tintoré, M., Brieva, L., Aymerich, F., Río, J., Porcel, J., Borrás, C., Nos, C., & Rovira, À. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509106937 · Cited by 117
Imaging correlates of decreased axonal Na + /K + ATPase in chronic multiple sclerosis lesions
Young, E. A., Fowler, C. D., Kidd, G. J., Chang, A., Rudick, R. A., Fisher, E., & Trapp, B. D. (2008) · Annals of Neurology · doi:10.1002/ana.21381 · Cited by 116
Multiple Sclerosis Therapeutics
Rudick, R. A., & Cohen, J. A. (2018) · CRC Press eBooks · doi:10.3109/9780203639115 · Cited by 115
Cervical cord lesion load is associated with disability independently from atrophy in MS
KEARNEY, H. F., Altmann, D. R., Samson, R. S., Yiannakas, M. C., Wheeler‐Kingshott, C. A. M. G., Ciccarelli, O., & Miller, D. H. (2014) · Neurology · doi:10.1212/wnl.0000000000001186 · Cited by 113
Cutter, W. J., Daly, E., Robertson, D., Chitnis, X. A., van Amelsvoort, T., Simmons, A., Ng, V., Williams, B. S., Shaw, P., Conway, G. S., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.026 · Cited by 111
Meuth, S. G., Simon, O. J., Grimm, A. M., Melzer, N., Herrmann, A. M., Spitzer, P., Landgraf, P., & Wiendl, H. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.11.013 · Cited by 108
Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors
Ouardouz, M., Coderre, E., Basak, A., Chen, A. A., Zamponi, G. W., Hameed, S., Rehak, R., Yin, X., Trapp, B. D., & Stys, P. K. (2009) · Annals of Neurology · doi:10.1002/ana.21533 · Cited by 108
MULTIPLE SCLEROSIS AND EPSTEIN-BARR VIRUS
Warner, H. B., & Carp, R. I. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91527-0 · Cited by 107
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
Castillo‐Triviño, T., Braithwaite, D., Bacchetti, P., & Waubant, E. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066308 · Cited by 106
Pardo, A. D., Amico, E., Favellato, Μ., Castrataro, R., Fucile, S., Squitieri, F., & Maglione, V. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt615 · Cited by 103
Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis
Schlaeger, R., Papinutto, N., Zhu, A. H., Lobach, I. V., Bevan, C. J., Bucci, M., Castellano, A., Gelfand, J. M., Graves, J., Green, A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0993 · Cited by 100
A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients
Frank, J. A., Richert, N. D., Lewis, B. K., Bash, C. N., Howard, T., Civil, R. H., Stone, R. D., Eaton, J. K., McFarland, H. F., & Leist, T. P. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms768oa · Cited by 99
Oral treatment for multiple sclerosis
Killestein, J., Rudick, R. A., & Polman, C. H. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70228-9 · Cited by 98
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
Mishra, M. K., Wang, J., Keough, M. B., Fan, Y., Silva, C., Sloka, S., Hayardeny, L., Brück, W., & Yong, V. W. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.67 · Cited by 94
Meuth, S. G., Herrmann, A. M., Simon, O. J., Siffrin, V., Melzer, N., Bittner, S., Meuth, P., Langer, H. F., Hallermann, S., Boldakowa, N., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4339-09.2009 · Cited by 94
Corsiero, E., Bombardieri, M., Manzo, A., Bugatti, S., Uguccioni, M., & Pitzalis, C. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.04.013 · Cited by 91
Traboulsee, A. L., Dehmeshki, J., Peters, K. R., Griffin, C., Brex, P., Silver, N., Ciccarelli, O., Chard, D., Barker, G. J., Thompson, A. J., et al. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms958oa · Cited by 90
Gender-related differences in MS: a study of conventional and nonconventional MRI measures
Antulov, R., Weinstock‐Guttman, B., Cox, J., Hussein, S. M., Durfee, J., Caiola, C., Dwyer, M. G., Bergsland, N., Abdelrahman, N. G., Stosic, M., et al. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508099479 · Cited by 87
Mitsunaga, Y., Ćirić, B., Keulen, V. P. V., Warrington, A. E., Soldán, M. M. P., Bieber, A. J., Rodriguez, M., & Pease, L. R. (2002) · The FASEB Journal · doi:10.1096/fj.01-0994fje · Cited by 85
Filippi, M., Campi, A., Martinelli, V., Colombo, B., Yousry, T. A., Canal, N., Scotti, G., & Comi, G. P. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.5.540 · Cited by 85
Sodium Channel Expression Within Chronic Multiple Sclerosis Plaques
Black, J. A., Newcombe, J., Trapp, B. D., & Waxman, S. G. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181462841 · Cited by 84
Spatio-Temporal Patterns of Demyelination and Remyelination in the Cuprizone Mouse Model
Tagge, I., O’Connor, A., Chaudhary, P., Pollaro, J., Berlow, Y., Chalupsky, M., Bourdette, D., Woltjer, R., Johnson, M., & Rooney, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152480 · Cited by 81
Pradat, P., Kennel, P., Naimi-Sadaoui, S., Finiels, F., Orsini, C., Revah, F., Delaère, P., & Mallet, J. J. (2001) · Human Gene Therapy · doi:10.1089/10430340152710577 · Cited by 80
Primary progressive multiple sclerosis: progress and challenges
Rice, C. M., Cottrell, D., Wilkins, A., & Scolding, N. J. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304140 · Cited by 78
Preziosa, P., Rocca, M. A., Mesaroš, Š., Pagani, E., Stošić-Opinćal, T., Kačar, K., Absinta, M., Caputo, D., Drulovic, J. S., Comı, G., et al. (2011) · Radiology · doi:10.1148/radiol.11110315 · Cited by 77
Axon loss in multiple sclerosis
Scolding, N. J., & Franklin, R. J. M. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60463-1 · Cited by 76
Silver, N., Tofts, P. S., Symms, M. R., Barker, G. J., Thompson, A. J., & Miller, D. H. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700201 · Cited by 75
Neurotrophins, neuroprotection and the blood-brain barrier.
Pardridge, W. M. (2002) · PubMed · Cited by 69
Testosterone amplifies excitotoxic damage of cultured oligodendrocytes
Caruso, A., Gerevini, V. D. G., Castiglione, M., Marinelli, F., Tomassini, V., Pozzilli, C., Caricasole, A., Bruno, V., Caciagli, F., Moretti, A., et al. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2004.02284.x · Cited by 67
Harrison, D. M., Oh, J., Roy, S., Wood, E. T., Whetstone, A., Seigo, M. A., Jones, C. K., Pham, D. L., van Zijl, P. C. M., Reich, D. S., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514558134 · Cited by 65
MS Cortical Lesions on DIR: Not Quite What They Seem?
Sethi, V., Muhlert, N., Ron, M. A., Golay, X., Wheeler‐Kingshott, C. A. M. G., Miller, D. H., Chard, D., & Yousry, T. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078879 · Cited by 58
Feng, J., Misu, T., Fujihara, K., Sakoda, S., Nakatsuji, Y., Fukaura, H., Kikuchi, S., Tashiro, K., Suzumura, A., Ishii, N., et al. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1070oa · Cited by 51
Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes
Louapre, C., & Lubetzki, C. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515587598 · Cited by 43
The Role of Neurotrophins in Multiple Sclerosis—Pathological and Clinical Implications
Kalinowska, A., & Losy, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131013713 · Cited by 43
Al‐Izki, S., Pryce, G., Hankey, D. J. R., Lidster, K., von Kutzleben, S., Browne, L., Clutterbuck, L. A., Posada, C., Chan, A. W. E., Amor, S., et al. (2013) · Brain · doi:10.1093/brain/awt324 · Cited by 43
Hohlfeld, R. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.03.012 · Cited by 42
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
Buttmann, M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.38 · Cited by 40
Multiple Sclerosis Therapeutics
(2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986 · Cited by 39
Progressive Multiple Sclerosis and Gray Matter Pathology: An MRI Perspective
Inglese, M., Oesingmann, N., Casaccia, P., & Fleysher, L. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20247 · Cited by 38
Antibody-mediated remyelination operates through mechanism independent of immunomodulation
Ćirić, B., Keulen, V. P. V., Soldán, M. M. P., Rodriguez, M., & Pease, L. R. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.11.002 · Cited by 37
Straßburger-Krogias, K., Ellrichmann, G., Krogias, C., Altmeyer, P. J., Chan, A., & Gold, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614544466 · Cited by 35
Prospects of repair in multiple sclerosis
Yong, V. W. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70006-1 · Cited by 34
Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study
Ukkonen, M., Vahvelainen, T., Hämäläinen, P. I., Dastidar, P., & Elovaara, I. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509106231 · Cited by 31
Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis
Lugaresi, A., Caporale, C. M., Farina, D., Marzoli, F., Bonanni, L., Muraro, P. A., Luca, G. D., Iarlori, C., & Gambi, D. (2001) · Neurological Sciences · doi:10.1007/s100720170026 · Cited by 29
Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis
Farez, M., & Correale, J. D. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.12.022 · Cited by 29
Self-citationSbardella, E., Greco, A., Stromillo, M. L., Prosperini, L., Puopolo, M., Cefaro, L. A., Pantano, P., Stefano, N. D., Minghetti, L., & Pozzilli, C. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512457721 · Cited by 26
Neurodegeneration in multiple sclerosis is a process separate from inflammation: No
Hutchinson, M. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515612244 · Cited by 22
Patterns of disease activity in multiple sclerosis.
Thompson, A. J., Miller, D. H., MacManus, D. G., & McDonald, W. I. (1990) · BMJ · doi:10.1136/bmj.301.6742.44-a · Cited by 16
Tourbah, A., Lebrun‐Frénay, C., Edan, G., Clanet, M., Papex, C., Vukusic, S., de Sesze, J., Debouverie, M., Gout, O., Clavelou, P., et al. (2015) · HAL · Cited by 5
Research works printed but not linked: 8
- Andersson, 1999, Multiple sclerosisthatis progressive from the time of onset: clinical characteristicsand progression of disability, Ann Neurol, 56, 1138
- 10.1136/jnnp.2010.205021 · doi:10.1136/jnnp.2010.205021
- Cadavid, 2015, BIIBo33, anti-LINGO treatment of relapsing-remitting Multiple Sclerosis: Basal data of the Phase 2 SYNERGY Trial, Neurology, 84 (14 Suppl), P7204, 10.1212/WNL.84.14_supplement.P7.204 · doi:10.1212/wnl.84.14_supplement.p7.204
- Cadavid, 2016, Evidence that the Anti-Lingo-1 monoclonal antibody BIIBo33protects against multifocal visual evoked potential amplitud loss in the fellow eye of subjects with unilateral acute optic neuritis, Neurology, 86 (16 Suppl), I10.009, 10.1212/WNL.86.16_supplement.I10.009 · doi:10.1212/wnl.86.16_supplement.i10.009
- 10.1007/s00415-011-6212-9 · DOI
- 10.1111/j.1755-5949.2008.00072.x · doi:10.1111/j.1755-5949.2008.00072.x
- 10.1191/1352458503ms970oa · doi:10.1191/1352458503ms970oa
- Tourbah A Lebrun-Frenay C Edan G Clanet M Papex C Vukusic S . 24-Month-treatment with-MD1003 (high doses of Biotin) in progressive multiple sclerosis: results of the MS-SPI trial extension phase. Neurology 2016; 86: Suppl S49.004 · doi:10.26226/morressier.59a3e8b7d462b8028d895787
Cited by
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Takata, F., Nakagawa, S., Matsumoto, J., & Dohgu, S. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661838 · Cited by 651
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Lin, J., Zhou, J., & Xu, Y. (2023) · Brain · doi:10.1093/brain/awad070 · Cited by 271
“38 Considering the pathogenesis of PMS, which is characterized by chronic inflammation compartmentalized behind a closed blood–brain barrier, 3 we explored the causal proteins for MS not only in the plasma but also in the CSF and compared their effects thereafter.”
Secondary Progressive Multiple Sclerosis: New Insights
Cree, B. A. C., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Pozo Ramajo, A., Murphy, N., & Lassmann, H. (2021) · Neurology · doi:10.1212/wnl.0000000000012323 · Cited by 260
Metadata
- Authors
- Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-29
- Volume
- 140
- Issue
- 3
- Pages
- aww258
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2544079919
- Cited by
- 573
- References
- 181
- FWCI
- 23.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.